XBI
State Street SPDR S&P Biotech ETF
Set alert
155.98 USD -1.81 -1.15%
154.22 Day range 159.76
108.04 52-week range 169.55
- YTD
- +27.93%
- 1 year
- +39.38%
- Open
- 156.68
- Prev close
- 157.79
- Mkt cap
- 8.25B
- Vol
- 9.10M
- Avg vol
- 8.91M
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 154.22
- High
- 159.76
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 156.75
- 200-d avg
- 141.50
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 156.75
- 200-day average
- 141.50
Analyst view
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
About State Street SPDR S&P Biotech ETF
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
News
- Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
- ETFs That You May Consider Amid a Strengthening Biotech Outlook
- Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
- Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
- Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million
- SPDR S&P Biotech ETF $XBI Stock Sold by Banque Pictet & Cie SA
- Traders Purchase Large Volume of Call Options on SPDR S&P Biotech ETF (NYSEARCA:XBI)
- From Laggard to Leader: The Surprising Comeback of Healthcare
- Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
- SPDR S&P Biotech ETF $XBI Stock Acquired by Ayalon Insurance Comp Ltd.
Your note
Sign in to keep a note on XBI — it syncs with the Stock Master app.